Unlock full details of this profile with our free Lite plan!
Sign Up and Get Free AccessArsenalBio - About the company
ArsenalBio is a series C company based in San Francisco (United States), founded in 2019 by Ken Drazan. It operates as a Developer of immune cell therapies. ArsenalBio has raised $631M in funding from investors like Westlake Village Biopartners, T. Rowe Price and Arch Venture Partners. The company has 714 active competitors, including 246 funded and 174 that have exited. Its top competitors include companies like Moderna, BeiGene and Juno Therapeutics.
Company Details
Developer of immune cell therapies. The company develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies.
- Website
- arsenalbio.com
- Social
- Email ID
- *****@arsenalbio.com
Key Metrics
Founded Year
2019
Location
San Francisco, United States
Stage
Series C
Total Funding
$631M in 3 rounds
Latest Funding Round
Investors
Ranked
17th among 714 active competitors
Employee Count
178 as on Dec 31, 2022
Legal entities associated with ArsenalBio
ArsenalBio is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Feb 01, 2018 | - | 178 (as on Dec 31, 2021) | ||
- | 178 (as on Dec 31, 2022) |
Get your free copy of ArsenalBio's company profile
ArsenalBio's funding and investors
ArsenalBio has raised a total funding of $631M over 3 rounds. Its first funding round was on Oct 17, 2019. Its latest funding round was a Series C round on Jul 09, 2024 for $325M. 14 investors participated in its latest round, lead by Arch Venture Partners, Milky Way Investments Group, Regeneron Ventures, NVentures, T. Rowe Price and Rock Springs Capital.
ArsenalBio has 24 institutional investors including Westlake Village Biopartners, T. Rowe Price and Arch Venture Partners.
Here is the list of recent funding rounds of ArsenalBio:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jul 09, 2024 | $325M | Series C | 7640291 | 7405064 | |
Sep 06, 2022 | $221M | Series B | 7049138 | 8922627 | |
Oct 17, 2019 | $85M | Series A | 4015936 | 6411645 |
Access funding benchmarks and valuations. Sign up today!View details of ArsenalBio's funding rounds and investors
ArsenalBio's founders and board of directors
Founder? Claim ProfileThe founders of ArsenalBio is Ken Drazan. Ken Drazan is the CEO of ArsenalBio.
View details of ArsenalBio's Founder profiles and Board Members
ArsenalBio's employee count trend
ArsenalBio has 178 employees as of Dec 22. The total employee count is 91.0% more than what it was in Dec 21. Here is ArsenalBio's employee count trend over the years:Uncover ArsenalBio's growth story! Sign up today!Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ArsenalBio's Competitors and alternates
Top competitors of ArsenalBio include Moderna, BeiGene and Juno Therapeutics. Here is the list of Top 10 competitors of ArsenalBio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 80/100 | |
2nd | BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 78/100 | |
3rd | Juno Therapeutics 2013, Seattle (United States), Acquired | CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer. | $317M | 73/100 | |
4th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | 71/100 | |
5th | Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public | Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others | - | 69/100 | |
6th | Allogene Therapeutics 2018, San Francisco (United States), Public | Developer of chimeric antigen receptor cell therapy to treat cancer | $532M | 68/100 | |
7th | Developer of antibodies for treating cancer | - | 67/100 | ||
8th | Poseida Therapeutics 2015, San Diego (United States), Acquired | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | $324M | 66/100 | |
9th | Annexon 2011, San Francisco (United States), Public | Developer of antibodies to treat complement-mediated neurodegenerative diseases | $256M | 65/100 | |
10th | Lyell Immunopharma 2018, San Francisco (United States), Public | Developer of CAR- T therapy for cancer treatment | $493M | 65/100 | |
17th | ArsenalBio 2019, San Francisco (United States), Series C | Developer of immune cell therapies | $631M | 62/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ArsenalBio's competitors? Click here to see the top ones
ArsenalBio's Investments and acquisitions
ArsenalBio has made no investments or acquisitions yet.
Reports related to ArsenalBio
Here is the latest report on ArsenalBio's sector:
News related to ArsenalBio
Filter this listMedia has covered ArsenalBio for a total of 4 events in the last 1 year, 1 of them has been about people movement.
•
Arsenalbio, Hejia Biotech, And Shengshitaike Completed A New Round Of FinancingYaorongyun Digital Technology•Oct 26, 2024•ArsenalBio, Hejiachemical, CGene Tech
•
Nate Hardy to Join Arsenal Biosciences, Inc. as Chief Financial OfficerBusiness Wire•Sep 16, 2024•ArsenalBio
•
ArsenalBio secures $325m to develop cell therapy programmesPharmaceutical Technology•Sep 05, 2024•ArsenalBio, Arch Venture Partners, Luma Group, Milky Way Holdings and 14 others
•
ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in towFierce Biotech•Sep 04, 2024•ArsenalBio, Arch Venture Partners, Regeneron Pharmaceuticals, NVentures
•
•
•
Simcha Therapeutics Announces its Scientific Advisory Board, Comprised of Renowned Experts in Immunology and OncologyBusiness Wire•Aug 22, 2023•Simcha Therapeutics, ArsenalBio
•
ArsenalBio Announces Presentations Highlighting Preclinical Data on AB-1015 and AB-2100 at ASGCT Annual MeetingBusiness Wire•May 16, 2023•ArsenalBio
•
Thermo Fisher Scientific and Arsenal Biosciences Collaborate to Support Clinical Manufacturing of Autologous T-Cell TherapiesBusiness Wire•Mar 29, 2023•Thermo Fisher Scientific, ArsenalBio
•
ArsenalBio Announces First Patient Dosed in Phase 1 Clinical Trial of AB-1015 in Development as a Treatment for Ovarian CancerBusiness Wire•Jan 05, 2023•ArsenalBio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about ArsenalBio
Explore our recently published companies
- Lilac Labs - San Francisco based, 2022 founded, Seed company
- Apitrailers - Unfunded company
- Officeequipmenthub - Unfunded company
- Tnec - Vancouver based, 2015 founded, Unfunded company
- Mahilanidhi - Unfunded company
- German Offshore Wind Energy Foundation - Varel based, 2005 founded, Funding Raised company